Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 655

Results For "AI"

9359 News Found

Aurobindo Pharma Foundation and Rotary Clubs donated 800 bicycles
News | August 27, 2022

Aurobindo Pharma Foundation and Rotary Clubs donated 800 bicycles

The drive also conducted a mega health camp, cancer screening for women and men, ENT screening for children, and blood donation drive


Benvic acquires specialty U.S. compounder Chemres
News | August 27, 2022

Benvic acquires specialty U.S. compounder Chemres

The ninth acquisition since 2018


Jubilant receives EIR from USFDA for its radiopharmaceuticals manufacturing facility Montreal Canada
News | August 27, 2022

Jubilant receives EIR from USFDA for its radiopharmaceuticals manufacturing facility Montreal Canada

With the receipt of the EIR, the inspection stands successfully closed.


US FDA inspection at Gland Pharma's Dundigal facility, Hyderabad
News | August 26, 2022

US FDA inspection at Gland Pharma's Dundigal facility, Hyderabad

The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.


10th Merck Bioforum India 2022 on Sept. 6-8
News | August 26, 2022

10th Merck Bioforum India 2022 on Sept. 6-8

This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape


JB Pharma ranks 23 in Indian pharma market
News | August 26, 2022

JB Pharma ranks 23 in Indian pharma market

JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.


Pristyn Care witnesses industry highest adoption of EMR
Healthcare | August 26, 2022

Pristyn Care witnesses industry highest adoption of EMR

99% of Pristyn Doctors are using EMR facility on its doctor app


Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer
Drug Approval | August 26, 2022

Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients


Lupin receives approval from US FDA for Formoterol Fumarate Inhalation Solution
Drug Approval | August 25, 2022

Lupin receives approval from US FDA for Formoterol Fumarate Inhalation Solution

Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of US $282 million in the US